MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
8:10 AM | Saturday | Aug 15, 2026 Seeking Alpha

How To Invest $100,000 In A Retiree's SWAN Income Portfolio

News Thumbnail
11:29 AM | Thursday | Aug 13, 2026 Seeking Alpha

Wall Street Lunch: Trump's MMR Split Plan Faces FDA, Manufacturing Hurdles

News Thumbnail
11:01 AM | Thursday | Aug 13, 2026 Zacks Investment Research

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

News Thumbnail
7:53 AM | Wednesday | Aug 12, 2026 247 Wallst

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More

News Thumbnail
12:50 PM | Tuesday | Aug 11, 2026 CNBC

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

News Thumbnail
10:50 AM | Tuesday | Aug 11, 2026 Zacks Investment Research

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

News Thumbnail
1:15 AM | Friday | Aug 7, 2026 Barrons

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

News Thumbnail
12:00 PM | Thursday | Aug 6, 2026 24/7 Wall Street

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

News Thumbnail
10:31 AM | Thursday | Aug 6, 2026 Zacks Investment Research

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

News Thumbnail
6:45 AM | Thursday | Aug 6, 2026 Business Wire

U.S. FDA Accepts sBLA for ENFLONSIAâ„¢ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

News Thumbnail

How To Invest $100,000 In A Retiree's SWAN Income Portfolio

Seeking Alpha

8:10 AM | Saturday | Aug 15, 2026

news photo
Loading...

The bull market that started in 2022 still continues, making the market somewhat overvalued, and we recommend proven strategies over investing in what is popular. A SWAN (Sleep Well At Night) income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning, especially suited for income investors and retirees. We provide a framework for a long-term portfolio with multiple buckets that is flexible to suit individual needs, limitations, and preferences.

Read full article redirect
8:10 AM | Saturday | Aug 15, 2026

How To Invest $100,000 In A Retiree's SWAN Income Portfolio

Seeking Alpha

The bull market that started in 2022 still continues, making the market somewhat overvalued, and we recommend proven strategies over investing in what is popular. A SWAN (Sleep Well At Night) income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning, especially suited for income investors and retirees. We provide a framework for a long-term portfolio with multiple buckets that is flexible to suit individual needs, limitations, and preferences.

Read full article arrow
News Thumbnail
11:29 AM | Thursday | Aug 13, 2026

Wall Street Lunch: Trump's MMR Split Plan Faces FDA, Manufacturing Hurdles

Seeking Alpha

Merck (MRK) and GSK face regulatory and manufacturing hurdles to producing individual MMR vaccines, with FDA approval likely to take years. IBM (IBM) is deepening its AI capabilities by integrating OpenAI models into its consulting platform, targeting enterprise AI and cybersecurity solutions.

Read full article arrow
News Thumbnail
11:01 AM | Thursday | Aug 13, 2026

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

Zacks Investment Research

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.

Read full article arrow
News Thumbnail
7:53 AM | Wednesday | Aug 12, 2026

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More

247 Wallst

With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.

Read full article arrow
News Thumbnail
12:50 PM | Tuesday | Aug 11, 2026

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

CNBC

President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.

Read full article arrow
News Thumbnail
10:50 AM | Tuesday | Aug 11, 2026

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Zacks Investment Research

Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.

Read full article arrow
News Thumbnail
1:15 AM | Friday | Aug 7, 2026

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Barrons

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

Read full article arrow
News Thumbnail
12:00 PM | Thursday | Aug 6, 2026

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

24/7 Wall Street

Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.

Read full article arrow
News Thumbnail
10:31 AM | Thursday | Aug 6, 2026

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

Zacks Investment Research

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Aug 6, 2026

U.S. FDA Accepts sBLA for ENFLONSIAâ„¢ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIAâ„¢ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.

Read full article arrow
News Thumbnail